Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...

Shares of Moderna MRNA rose nearly 16% yesterday after a couple of SEC filings showed that two board members bought shares on ...

Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...

Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

A German court on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna .

As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech ...

Moderna Inc. expects to launch a personalized cancer vaccine that it’s developing with Merck & Co. by 2027, one of its top ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

MODERNA (MRNA, Financial) secured a major legal win in its COVID-19 vaccine patent dispute with Pfizer (PFE, Financial) and ...

For now, Moderna may be a good stock to put on a watch list, but it's likely too risky and volatile for the vast majority of ...

Arbutus Biopharma and Genevant Sciences are broadening the scope of their patent infringement claims against Moderna with ...